Table 2.
Results of Point-of-Care Testing for Detection of Toxoplasma IgG and/or IgM Antibodies
| POC Kit | Toxoplasma Antibodies | IgG+ (Positives/Reference Testing at PAMF-TSL) (%) |
IgG−/IgM− (Positives/Reference Testing at PAMF-TSL) (%) |
Toxoplasma Antibodies | IgM+a (Positives/Reference Testing at PAMF-TSL) (%) |
IgM−a (Positives/Reference Testing at PAMF-TSL) (%) |
|---|---|---|---|---|---|---|
| Biopanda | IgG | 170 of 170 (100) |
3 of 80 (3.8) |
IgM | 51 of 82b (62.2) |
19 of 165 (11.5) |
| OnSite | IgG | 170 of 170 (100) |
2 of 80 (2.5) |
IgM | 23 of 82b (28) |
4 of 165 (2.4) |
| LDBIOc | IgG/IgM Combined | 170 of 170 (100) |
1 of 80 (1.3) |
IgG/IgM Combined | 82 of 82b (100) |
NA |
Abbreviations: CDC, Centers for Disease Control and Prevention; CDC-HSP, CDC Toxoplasma 1998 Human Serum Panel; Ig, immunoglobulin; NA, not applicable; PAMF-TSL, Palo Alto Medical Foundation, Toxoplasma Serology Laboratory; POC, point of care.
aAll IgM positive sera were also IgG positive by reference testing. The IgM negative sera were either IgG+IgM− sera (n = 85) or IgG−IgM− sera (n = 80).
bThree of 85 samples (from the CDC-HSP 1998) were excluded from the calculation of analytical sensitivity for IgM that were provided to us by the CDC report, because PAMF-TSL IgM-ELISA results were <2.0 units (cutoff for positive).
cLDBIO POC test detects in combination Toxoplasma IgG/IgM.